Dong Y, Wang Z, Hu X, Sun Y, et al. [(18)F]AlF-NOTA-FAPI-04 PET/CT for Predicting Pathologic Response of Resectable Esophageal Squamous Cell Carcinoma to Neoadjuvant Camrelizumab and Chemotherapy: A Phase II Clinical Trial. J Nucl Med 2024 Sep 26:jnumed.124.268557. doi: 10.2967/jnumed.124.268557.
PMID: 39327020